Rona Therapeutics Unveils Promising Phase 1 Results of RN0361 at AHA 2025 Scientific Sessions Rona Therapeutics showcased the promising Phase 1 data of RN0361 at the AHA 2025, indicating a potential breakthrough in treating hypertriglyceridemia.

Rona Therapeutics Unveils Promising Phase 1 Results of RN0361 at AHA 2025 Scientific Sessions #USA #New_Orleans #Rona_Therapeutics #RN0361 #APOC3

Rona Therapeutics Unveils Promising Phase 1 Results for RN0361 at AHA 2025 Rona Therapeutics showcased Phase 1 findings for RN0361, a novel siRNA targeting ApoC3, at AHA 2025, showing excellent efficacy and safety.

Rona Therapeutics Unveils Promising Phase 1 Results for RN0361 at AHA 2025 #USA #New_Orleans #Rona_Therapeutics #RN0361 #siRNA

Rona Therapeutics Secures FDA IND Clearance for RN0361: A Novel siRNA for Hypertriglyceridemia Management Rona Therapeutics has announced FDA IND clearance to advance RN0361, a targeted siRNA therapy for managing hypertriglyceridemia in patients after promising Phase 1 results.

Rona Therapeutics Secures FDA IND Clearance for RN0361: A Novel siRNA for Hypertriglyceridemia Management #Shanghai #USA #Rona_Therapeutics #RN0361 #siRNA_therapy

Rona Therapeutics Gets FDA Approval for Phase 2 Study of Innovative Hypertriglyceridemia Treatment Rona Therapeutics has received FDA clearance to begin Phase 2 trials for RN0361, a targeted siRNA treatment for managing hypertriglyceridemia, aiming to improve patient outcomes.

Rona Therapeutics Gets FDA Approval for Phase 2 Study of Innovative Hypertriglyceridemia Treatment #Shanghai #USA #FDA_Clearance #Rona_Therapeutics #RN0361